Analysearchiv
Alle Analysen
Seite 18 von 45 · 1080 Analysen
40/100
Goldwind Zen Horizon Framework Deep-Dive Research
Goldwind is the world's largest wind-turbine OEM, positioned at the center of the electrification and clean-energy supply chain. The cyclical recovery is real, with FY25 net profit up 49%, anti-involution price discipline repairing manufacturing gross margin, and overseas gross margin more than doubling, but the A-share has already rallied 2.5x from ¥9 to ¥23 while PE-TTM sits near 35x, manufacturing margin remains in single digits, profit quality depends heavily on investment gains, and cash flow is weak. Report rating Watch: wait for a better margin of safety, with an ideal buy price at or below ¥17 and the H-share offering a cheaper expression of the same business.
U.S. Market Close Daily | 2026-06-05
A strong jobs report lifted rate-hike expectations, with tech and chips leading the decline. Rating Watch: U.S. equities rolled over from highs as risk appetite faded and the market shifted from pricing growth delivery to repricing rates.
44/100
Sony Group Zen Horizon Framework Deep-Dive Research
A diversified entertainment and imaging group with high business quality at a fair price. Record operating profit of ¥1.45 trillion, forward P/E of ~17×, and a largely closed conglomerate discount after the financial spin-off support the case, but the gaming cycle is peaking, Samsung is taking some Apple image-sensor orders, and Sony lacks a single high-growth engine. Research rating Hold: a fair-quality compounder whose ideal buy price is ≤¥2,900.
29/100
MARA Holdings Deep Dive (Zen Horizon): The Bitcoin Mining King at the Crossroads of Deleveraging and an AI Energy Pivot
The world's largest Bitcoin miner by hashrate and the fourth-largest corporate BTC holder (about 35,300 coins). But on an all-in mining cost basis it now loses money on every coin it mines, has burned cash and diluted shares nearly 3.8x over three years, lags peers on the AI pivot with zero hyperscaler signings, and trades at a 2.4x mNAV that is richer than MSTR. No margin of safety. Rating Watch: a transforming cycle stock whose AI option is already paid for at today's price.
37/100
Joby Aviation (JOBY.US) Zen Horizon Research Report
Joby is the global leader in eVTOL air taxis with the most advanced certification progress, a market cap of about $11 billion, net cash of about $1.765 billion, and EV of about $9.2 billion. The core case is real certification leadership backed by Toyota as its largest shareholder, a six-year Dubai exclusive, and Delta, set against annual cash burn above a $930 million net loss and an ITC exclusion-order investigation that threatens the Delta partnership. Research rating Watch: best-in-class quality, fully priced leadership premium, and a need to wait for certification and ITC de-risking or a better entry price.
27/100
Victrex (VCT.LSE) Zen Horizon Framework Deep Dive: The World's PEEK King Has Fallen 80%—A Great Asset Meets Structural Price Resets, a China Plant Write-Down, and a Dividend Cut Hanging Overhead
The world's largest maker of PEEK (a high-performance engineering plastic), Victrex builds metal-replacement specialty polymers sold into aerospace, medical, electronics, and automotive; its leadership position, vertical integration, and Invibio implant-grade medical franchise (~75% gross margin) form a real moat. It is now hitting a structural pricing reset from low-cost Chinese PEEK (roughly half the import price)—volumes are rising but profits are falling, and underlying operating margin has been halved from 28% to 16.5%. Rating Watch: a world-class asset facing structural margin erosion and a likely dividend cut, cheap but not yet safe.
41/100
AeroVironment (AVAV) Zen Horizon Research Report
AeroVironment is a core U.S. supplier of loitering munitions (Switchblade) and small drones (Puma/Raven), positioned directly in the strongest defense tailwind of this cycle: drone dominance. The central thesis is that a first-rate franchise is meeting a costly integration stumble after the $4.1 billion all-stock BlueHalo acquisition, with the Q3 revenue miss, gross margin compression from 38% to 24%, a $151 million space goodwill impairment, lowered full-year guidance, a GAAP loss, and securities class-action litigation all surfacing at once. Rating Watch: a durable compounder in a powerful market, but the better entry point is after integration stabilizes or below $175.
46/100
74Buffett
BWX Technologies (BWXT) Zen Horizon Research Report
BWX Technologies is the de facto sole-source manufacturer of U.S. Navy nuclear propulsion reactors, cores, and fuel, with a nearly impregnable moat. The core thesis is anchored by roughly $7 billion of government backlog and rigid multi-year national programs such as the Columbia- and Virginia-class submarines, with additional nuclear renaissance options in Project Pele microreactors, BWRX-300 reactor pressure vessels, and medical isotopes. Report rating Watch: a world-class business is already priced close to full value, leaving limited margin of safety before option value converts into earnings.
35/100
Archer Aviation (ACHR.US) Zen Horizon Research Report
Archer Aviation is the second major global eVTOL air-taxi contender, with a market cap of about $4.85 billion, net cash of about $1.7 billion ($2.23/share), and EV of about $3.15 billion. FAA certification has closed Stage 3 and net cash covers roughly two years, but the company still has almost no commercial revenue, burns more than $600 million a year, has expanded its share count by 166% in two years, and trails Joby by roughly one certification stage. Rating Watch: after falling by half to $6.38, the stock still lacks a margin of safety.
47/100
27Buffett
Samsung Biologics (207940) Zen Horizon Framework Deep Dive: A Global CDMO Champion Newly Purified by Spin-Off, Where an Excellent Business Meets a Rich Price and Unproven BIOSECURE Upside
Samsung Biologics is the world's largest biologics CDMO, a contract development and manufacturing platform that became a pure-play CDMO after spinning off Samsung Bioepis in November 2025. Its core case rests on world-leading capacity of roughly 780,000 liters, operating margin near 45%, revenue growth above 30%, relationships with 17 of the world's top 20 pharmaceutical companies, and a $21.4B backlog, but the valuation already prices in capacity leadership and BIOSECURE upside that has not yet been proven in orders. Report rating Hold: a top-tier compounder deserves a premium, but at the current price the margin of safety is thin.
35/100
JL MAG Rare-Earth (300748) Zen Horizon Framework Deep Dive: A Global Rare-Earth Permanent Magnet Leader, With a V-Shaped Earnings Rebound Meeting a Rich Valuation and a Robotics Narrative
JL MAG Rare-Earth is the clear A-share leader in rare-earth permanent magnets, focused on high-performance NdFeB materials for NEVs, inverter air conditioners, wind power, and robotics. The core thesis is a V-shaped earnings rebound, with 2024 attributable net profit of CNY 290 million rising to CNY 706 million in 2025, driven mainly by higher praseodymium-neodymium prices and EV volume growth. Report rating Watch: a high-quality cyclical leader whose good news and unproven robotics option are already largely prepaid in the share price.
27/100
Sunshine Silver Mining & Refining (SSMR): A Zen Horizon Deep Dive
A development-stage silver miner that listed on 2026-06-04, anchored by Idaho's historic Sunshine silver mine (about 264 million ounces of silver resource, zero reserves, only a PEA-level initial assessment). Record-high silver prices plus a domestic U.S. antimony option are the bright spots, but production is unlikely before late 2028 and multiple rounds of dilution will be needed before then. Rating Watch: a genuinely good asset priced far too early and far too richly, with no margin of safety at the current price.
36/100
92Buffett
Roche Zen Horizon Framework Deep Dive: A Diagnostics and Pharma Giant Past the Patent Cliff, with a Fair Price and Debated Growth
Roche is the global leader in in vitro diagnostics and a top-tier pharmaceutical company in oncology, neurology, and ophthalmology, with family control and CHF-denominated shares. The company has moved past its patent cliff, new medicines have filled an approximately USD 10 billion gap, and the group has returned to +7% constant-currency growth, though a strong Swiss franc has reduced reported growth to only +2% in CHF. Rating Hold: valuation is fair at roughly 16x forward PE with a 3% dividend, 27% below the 2022 high, while growth remains debated and obesity is the largest upside option.
43/100
Schrödinger (SDGR) Zen Horizon Research Report
Schrödinger is a physics-based computational drug discovery platform built around FEP+, a gold-standard method, with 19 of the world's top 20 pharma companies as software customers and additional upside from internal and partnered pipelines plus repeat equity monetizations. Its current market value is about $1.1 billion, with roughly $300 million of net cash, while the stock is down 86% from its 2021 peak. Research rating Hold: a real platform with a hard moat and cheap parts, but slower software growth and limited near-term catalysts keep the risk-reward balanced.
38/100
65Buffett
Hon Hai Precision (2317.TW) Zen Horizon Deep-Dive Research
The world's largest electronics manufacturing services (EMS) leader is being re-rated as AI servers, including roughly a 40% share in NVL72 racks, lift cloud and networking revenue above iPhone-related revenue for the first time. Yet gross margin is only 6% and net margin 2%, the profit pool sits with Nvidia rather than the assembler, PE-TTM is around 20x at a ten-year high, and the margin of safety is thin. Rating Hold: the ideal buy zone requires a pullback to below roughly TWD 220.
46/100
SiTime (SITM) Zen Horizon Research Report
SiTime is the only scaled MEMS precision-timing player globally, replacing quartz crystal oscillators at the physical-material level with silicon-based oscillators. Its MEMS segment share exceeds 80%, while AI data centers drove Q1'26 revenue up 88% and FY26 guidance to at least 80% growth, though the $3.2 billion acquisition of Renesas's timing business adds leverage, dilution, and integration uncertainty. Research rating Watch: a real moat and real growth, but the current price leaves little margin for error.
36/100
GlobalFoundries (GFS) Zen Horizon Research Report
GlobalFoundries is the only Western pure-play foundry with manufacturing capacity across the United States, Europe, and Singapore, built around RF-SOI, FD-SOI, automotive, power, silicon photonics, and trusted manufacturing. The core thesis is a scarce reshoring and silicon-photonics positioning offset by a mature-node foundry model with only 26% gross margin, far below TSMC's 62%, and cyclical revenue. Research rating Watch: a real strategic asset, but the stock has already moved ahead of Wall Street consensus and fundamental growth.
43/100
73Buffett
Sanhua Intelligent Controls (002050.SHE) Zen Horizon Deep-Dive Research
Sanhua Intelligent Controls is the global leader in refrigeration control components, a new-energy vehicle thermal-management Tier-1 supplier, and an actuator option on humanoid robotics. FY25 revenue reached 31.0 billion yuan, attributable net profit was 4.06 billion yuan (+31%), gross margin was 28.8%, ROE was 15.8%, and the balance sheet was close to net cash. Research rating Watch: a high-quality manufacturer at a demanding price, with too much value already assigned to an unproven robotics option.
37/100
Cognex Zen Horizon Framework Deep Dive: The Eyes of Machine Vision, a Great Business at an Expensive Price
Cognex is the world's second-largest machine-vision leader, with a 68% gross margin, a 24% FCF margin, zero debt, and Q1 revenue reaccelerating by 24%. The core issue is valuation: 76× TTM PE and 44× forward PE sit near the top of its historical range, at a premium to every comparable company, mostly by 2-3×, while the share price has doubled in six months and leaves no margin of safety. Research rating Watch: a high-quality business at an expensive price, with the real entry point around $40-49.
53/100
38Buffett
Credo (CRDO) Zen Horizon Report
The pioneer of the AI data center copper interconnect category (Active Electrical Cable, AEC) and the leader with roughly 75% share. FY2026 revenue tripled to $1.335 billion, with a 68% gross margin, 35% GAAP net margin, $1.4 billion in net cash, and almost no debt—a connectivity picks-and-shovels play that is top tier on both quality and growth. Rating Watch: a superb business bought at a price that has already prepaid years of flawless growth, with tail risks from customer concentration and geopolitics holding it down.
30/100
59Buffett
Amkor (AMKR) Zen Horizon Report
The world's second-largest and the largest U.S.-listed OSAT packaging-and-test house, with advanced packaging (HDFO/2.5D) at roughly 83% of revenue, an AI advanced-packaging portfolio guided to roughly triple in 2026, and Arizona as the only at-scale advanced-packaging capacity on U.S. soil (CHIPS Act subsidy, co-located with TSMC, anchored by Apple and Nvidia). This is a capital-heavy cyclical business running just 14% gross margin and about 6% operating margin, with Apple at roughly 30% of revenue. Rating Watch: a real strategic foothold bought right at the start of a capital-devouring phase, with the market already pricing in zero upside.
36/100
SMIC (0981.HK) Zen Horizon In-Depth Research
China's largest foundry and the only mainland player with advanced-node capability at DUV 7nm, SMIC generated FY25 revenue of USD 9.33 billion with a 21% gross margin, but ROE was only about 3%, free cash flow was about USD -5.2 billion, and profits relied heavily on government subsidies. The core debate is whether strategic indispensability, AI-driven mature-node pricing, and domestic substitution can offset weak returns, heavy capex, and export-control ceilings. Research rating Watch: a strategically important asset, but at the current price the risk-reward is skewed downward.
55/100
Astera Labs (ALAB): A Zen Horizon Report
The purest play on the AI server connectivity bottleneck, spanning four product lines (PCIe/CXL retimers, smart cable modules, CXL memory controllers, and the Scorpio fabric switch) plus the COSMOS software layer. It holds a de facto monopoly in Gen5 retimers, PCIe Gen6 already accounts for one-third of total revenue, FY2025 revenue hit $850 million (+115%), Q1 2026 reached $308 million in a single quarter (+93%), non-GAAP gross margin runs at 76%, GAAP has turned positive, and net cash sits near $1.2 billion. The business is a textbook chokehold. Rating Watch: a first-rate chokehold business priced so richly it leaves no room for any misstep.
46/100
62Buffett
WuXi AppTec Zen Horizon Framework Deep Dive: A Fine Business, a Fair Price, and an Unresolved Geopolitical Catch
WuXi AppTec is the global leader in small-molecule CRDMO, with the highest gross margin among peers and core recurring net profit still up 32.6%. The central thesis is that the business quality remains high, but the H-share price of HKD 125.6 sits only inside a neutral valuation band, lacks a margin of safety, and still carries unresolved BIOSECURE/1260H binary geopolitical risk plus ongoing controlling-shareholder selling. Research rating Watch: a high-quality compounder worth monitoring, but current price and unresolved tail risk do not justify a new-position entry.